Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
Edit Symbol List
Symbol Lookup
UTHR: Stock Quote & Summary Data
0.22%
| Last Sale | |
| Change Net / % |
|
| Best Bid / Ask | |
| 1y Target Est: | $ 56.25 |
| Today's High / Low | / |
| Share Volume | |
| 50 Day Avg. Daily Volume | 664,334 |
| Previous Close | $ 44.81 |
| 52 Wk High / Low | $ 50.48 / $ 23.815 |
| Shares Outstanding | 53,165,000 |
| Market Value | $ 2,387,640,150 |
| P/E Ratio | NE |
| Forward P/E (1yr) | 27.46 |
| Earnings Per Share | $ -1.30 |
| Annualized Dividend | N/A |
| Ex Dividend Date | N/A |
| Dividend Payment Date | Sep. 22, 2009 |
| Current Yield | N/A |
| Beta | 0.89 |
| NASDAQ Official Open Price: | $ 44.50 |
| Date of NASDAQ Official Open Price: | Nov. 20, 2009 |
| NASDAQ Official Close Price: | $ 44.91 |
| Date of NASDAQ Official Close Price: | Nov. 20, 2009 |
Intraday Chart |
| 5d | 1m | 6m | 12m | More Charting |
Have a Question About UTHR?
Ask your question about about United Therapeutics Corporation (UTHR) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!
Hot Topics in NASDAQ Answers
The most popular questions & answers in the
NASDAQ Answers Community:
Company Description (as filed with the SEC)
We are a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. Our key therapeutic platforms are: º • º Prostacyclin Analogs, which are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Our lead prostacyclin analog is Remodulin®, a treprostinil-based compound for the treatment of cardiovascular disease. Remodulin (treprostinil sodium) Injection, has been approved by the U.S. ... More ...
Links to all United Therapeutics Corporation (UTHR) Pages
Stock Analysis
Fundamentals
Holdings/Ownership
Company News for UTHR |
||
|
United Therapeutics Q3 Profit Rises On Revenue Growth - Update - RTT News 10/29/2009 4:00PM |
||
|
United Therapeutics Q3 Profit Up - Quick Facts - RTT News 10/29/2009 8:09AM |
||
|
United Therapeutics Corporation Reports Third Quarter 2009 Financial Results - PR Newswire 10/29/2009 7:00AM |
||
|
EU Body Recommends Generic Version Of Pfizer's Viagra - Dow Jones Business News 10/23/2009 11:39AM |
||
|
United Therapeutics Corporation to Announce Third Quarter 2009 Financial Results Before Market Open on Thursday, October 29, 2009 - PR Newswire 10/22/2009 7:00AM |
||
|
Quarterly Changes to the NASDAQ Q-50 Index - GlobeNewswire 09/11/2009 8:05PM |
||
|
United Therapeutics Board Declares Stock Split - Quick Facts - RTT News 09/01/2009 4:22PM |
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $ 0.69 |
| Quarterly EPS Est: | $ 0.26 |
| PEG Ratio: | 0.72 |
| Mean Recommendation: View Summary/View All |
1.84 |
